1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P5764
    TRAP-14 amide
    Inducer
    TRAP-14 amide, a proteinase activated receptor (PAR)-activating peptide, is a PAR agonist with an EC50 of 24 μM. TRAP-14 amide significantly induces platelet aggregation through ADP- and MMP-2-dependent pathways with Aspirin (HY-14654)-insensitivity. TRAP-14 amide also effectively increases glycoprotein (GP) Ib and GPIIb/IIIa surface expression and ADP release.
    TRAP-14 amide
  • HY-P4320
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10)
    Antagonist
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10), a decapeptide containing a cyclic RGD active sequence, is an Integrin αIIbβ3 antagonist that inhibits platelet and Adhesion of proMMP-13.
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10)
  • HY-P1930
    Risuteganib
    Inhibitor
    Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide. Risuteganib is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina.
    Risuteganib
  • HY-153807
    αvβ6 integrin inhibitor 2
    Inhibitor
    αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC50 of 96.5 nM (WO2020081154A1, example 19).
    αvβ6 integrin inhibitor 2
  • HY-172464A
    DSPE-PEG3400-cRGD
    DSPE-PEG3400-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG3400-cRGD can be used for drug delivery.
    DSPE-PEG3400-cRGD
  • HY-175287
    α5β1 integrin agonist-2
    Agonist
    α5β1 integrin agonist-2 (Compound 2) is a highly selective α5β1 integrin agonist (EC50=45.98 nM). α5β1 integrin agonist-2 enhances extracellular matrix adhesion and Akt/ERK signaling activation. α5β1 integrin agonist-2 is promising for research of ischemic stroke.
    α5β1 integrin agonist-2
  • HY-172463
    DSPE-PEG1000-cRGD
    DSPE-PEG1000-cRGD is a PEG compound which composed of DSPE and an αvβ3 targeting peptide (cRGD). cRGD peptide can specifically bind to αvβ3 on the surface of many cancer cells and neovascular cells. DSPE-PEG1000-cRGD can be used for drug delivery.
    DSPE-PEG1000-cRGD
  • HY-19151C
    Fuzapladib calcium
    Inhibitor
    Fuzapladib calcium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib calcium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib calcium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
    Fuzapladib calcium
  • HY-P11328
    GFOGER peptide
    Ligand
    GFOGER peptide is a α2β1, α1β1 and α11β1 integrin ligand peptide. GFOGER peptide can be recognized via directly interactions of integrins with its Glu and Arg residues, particularly binding to Glu through the metal ion-dependent adhesion site (MIDAS).
    GFOGER peptide
  • HY-P10323
    T7 Peptide
    T7 peptide is an endothelial cell-specific inhibitor. T7 peptide interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, PKB/Akt, and mTOR signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis.
    T7 Peptide
  • HY-157172
    MorHap
    Inhibitor
    MorHap is a heroin hapten. MorHap conjugated to tetanus toxoid (TT), palm-CV2, and to monophosphoryl lipid A (MPLA)-containing liposomes partially blocks heroin-induced analgesia and hyperlocomotion in mice. MorHap designed conjugates also significantly inhibits HIV-1 binding to α4β7 receptors. MorHap can be used in research to develop vaccines related to heroin addiction and HIV-1 infection.
    MorHap
  • HY-N2587R
    Irigenin (Standard)
    Inhibitor
    Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
    Irigenin (Standard)
  • HY-P5021
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
    99.86%
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer.
    Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)
  • HY-N2584AR
    Isoxanthohumol (Standard)
    Inhibitor
    Isoxanthohumol (Standard) is the analytical standard of Isoxanthohumol (HY-N2584A). This product is intended for research and analytical applications. Isoxanthohumol is an orally active flavonoid compound. Isoxanthohumol has biological activities such as anti-tumor, anti-inflammatory, antioxidant, antiviral, antifungal, and inhibition of adipogenesis. Isoxanthohumol can induce apoptosis, autophagy, and migration of tumor cells. Isoxanthohumol is active against viruses such as HSV, BVDV, CMV, and Rhino. Isoxanthohumol can be used for the research of tumors, metabolic, and inflammatory diseases.
    Isoxanthohumol (Standard)
  • HY-125668
    Ro 43-5054
    Ro 43-5054 is a platelet glycoprotein IIb-IIIa receptor antagonist. Ro 43-5054 can be used in the research of early reocclusion after thrombolytic therapy.
    Ro 43-5054
  • HY-17369R
    Tirofiban hydrochloride monohydrate (Standard)
    Antagonist
    Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.
    Tirofiban hydrochloride monohydrate (Standard)
  • HY-175636
    ITGB3-IN-1
    Inhibitor
    ITGB3-IN-1 is an orally active integrin subunit beta 3 ITGB3 inhibitor with a Kd of 7.26 μM. ITGB3-IN-1 exhibits potent anti-orthopoxvirus effects with an EC50 for vaccinia virus (VACV) of 1.82 μM. ITGB3-IN-1 inhibits hERG with an IC50 of 1.13 μM. ITGB3-IN-1 can be used for the study of orthopoxvirus.
    ITGB3-IN-1
  • HY-17369BR
    Tirofiban (Standard)
    Antagonist
    Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.
    Tirofiban (Standard)
  • HY-123277
    IMB-10
    Inhibitor
    IMB-10 is an αMβ2 integrin ligand. IMB-10 inhibits αMβ2-dependent migration and inflammation-induced neutrophil emigration.
    IMB-10
  • HY-12159A
    MK-0668 mesylate
    Antagonist
    MK-0668 mesylate is an amino acid-based, potent antagonist of unactivated VLA-4, with an IC50) of 0.13 nM in human whole blood. And MK-0668 mesylate exhibits IC50s of 0.19 nM in dogs, 0.21 nM in rhesus monkeys, and 0.4 nM in rats.
    MK-0668 mesylate
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.